IMPROVING HEALTH IMPROVING LIVES

ABOUT US
•Our Values
•Views And Positions
•Our History
•Leadership

For more than a century, MSD, a leading global biopharmaceutical company,has been inventing for life, bringing forward medicines and vaccines for the world's most challenging diseases. MSD is a trade name of Merck & Co., Inc.,with headquarters in Kenilworth, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola. For more information, visit www.msd.com

MSD in India

MSD operates its human health business in India through three separate legal entities: MSD Pharmaceuticals Private Limited, Organon (India) Private Limited, and Fulford (India) Limited. Since its existence in India, the company has moved quickly in laying the foundation for a business that is differentiated by its focus through launching innovative products relevant to India. MSD in India also has presence in Animal Health via MSD Animal Health with its vaccines facility located in Pune, Maharashtra.

Key therapeutic areas

MSD in India currently operates in various therapeutic areas in human health, including Metabolics, Vaccines, Critical Care, Oncology, Women's Health, Dermatology, Respiratory, and Primary Care, and offers a strong and diversified product portfolio of over 35 brands. Launching our best in class and first in class products at India specific pricing, and supporting capacity-building initiatives and disease management programs, MSD in India devotes extensive time and energy to increasing access to medicines and vaccines through far-reaching programs and collaborative approach. MSD follows a comprehensive multi-stakeholder approach in all therapeutic areas relevant to our products. We work with partners from the government, non-government and private sectors on innovative approaches to increase access and overcome barriers to healthcare in India.

Commitment to India

At MSD, we are inspired by a shared vision and mission to save and improve lives. MSD has a long term commitment to India both in terms of bringing best in class products and also making necessary investments to serve the Indian patients. MSD will continue in its endeavor to help shape the healthcare paradigms in India through initiatives like responsible pricing, integrated disease management programs; partnerships for research & access; capacity building initiatives, amongst others. In addition to setting up a sales and marketing structure to market best in class products in India, MSD is also coordinating research projects with clinical investigators in India's leading hospitals and universities, for development of new drugs to address unmet medical needs for Indian patients. MSD in India manufactures 80% of the total volume of our products in India through local partners.

Caring for the society we serve

Corporate responsibility at MSD is a commitment to discovering innovative solutions to the world’s greatest health challenges while growing our business in a sustainable way. MSD embraces a commitment to its stakeholders, employees, neighbors, and others in the global communities where it lives and works. In India as well, the Company has a number of Corporate Social Responsibility, Disease Management programs and Capacity building initiatives in order to better serve the interest ofpatients and communities.

Forward-Looking Statement

Forward-Looking Statement of MSD & Co., Inc., Kenilworth, NJ, USA

This website of MSD & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; global trends toward healthcare cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.